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SUMMARYQ1
The apolipoprotein E "4 allele (APOE"4) is a well-established risk factor for Alzheimer’s disease (AD), but the mechanisms
for this association are not well understood. In addition, other risk and protecting factors are needed to explain the causality
of the disease. Sex steroid hormones, such as estradiol and testosterone, are thought to exert protective mechanisms in the
brain (Lee and McEwen, 2001). Lower levels of total estradiol and total testosterone in men with AD have been found
(Hogervorst et al., 2001; Rasmuson et al., 2002). The current study examined relations between APOE"4 and levels of total
testosterone and total estradiol in the risk of AD in men. Copyright # 2002 John Wiley & Sons, Ltd.
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SUBJECTS, METHODS AND RESULTS
We examined 116 male Caucasians from the Oxford
Project To Investigate Memory and Ageing
(OPTIMA). Fifty-one were autopsy confirmed
CERAD AD cases (mean age at episode: 75.3 years,
range: 58.8–89.5 years), 10 were diagnosed ‘probable
AD’ by NINCDS/ADRDA criteria (69.8 years, range:
57.4–88.8 years) and 55 were without cognitive
impairment and with CAMCOG scores  80 (73.6
years, range: 39.9–94.7 years). All had given their
informed consent prior to the study (Clarke et al.,
1998).
We analysed total testosterone using a competitive
enzyme immunoassay (Bayer1, Bayer Cooperation,
Tarrytown, NY, USA) in non-fasting blood serum
samples that had been stored at 70C. Serum had
been collected between 10 and 12 am. For total estra-
diol, duplicate serum samples were extracted with
ether. Estradiol was then assessed by radioimmunoas-
say using a highly specific rabbit antiserum. SHBG
levels were investigated using an immuno-enzymo-
metric assay (IEMA). Subjects were genotyped by
standard PCR methods for APOE and for the butyryl-
cholinesterase K variant.
Using a logistic regression model with age and
SHBG as co-variables, low testosterone (odds ratio
(OR)¼ 0.86, 95% confidence intervals (CI) 0.75–
0.99) and the APOE"4 testosterone interaction
(OR¼ 1.28, 95% CI¼ 1.07–1.54) were significantly
associated with AD, which suggested that the pre-
sence of the APOE"4 allele modified the risk of AD
associated with low testosterone levels. Entering
APOE"4 by itself as a risk factor for AD, gave an
OR of 7.72 (95% CI¼ 3.63 to 16.48, p< 0.01). In a
model where estradiol replaced testosterone, neither
estradiol alone nor the estradiolAPOE"4 interac-
tion was a significant predictor of AD.
Table 1 presents the results of analyses stratified by
diagnosis. The two main results were: first, testoster-
one levels were lower in APOE"4-positive controls
than in those without APOE"4; second, in men with-
out APOE"4, testosterone levels were lower in AD
than in controls. One of the lowest testosterone levels
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(1.6 nmol/l) was in the only control who was an
APOE"4 homozygote. With estradiol, levels were
lower in APOE"4 carriers, both in AD cases and in
controls.
We also examined two other alleles, apolipoprotein
E "2 (APOE"2) and the butyrylcholinesterase K
variant (BCHE-K). No significant association was
found between either allele and either steroid in any
analysis. Only a weak tendency was seen for
APOE"2-positive controls to have higher steroid
levels than those without APOE"2 (e.g. for testoster-
one: 20.2 nmol/l (n¼ 11) vs 16.5 nmol/l (n¼ 42),
p¼ 0.1, t-test).
COMMENT
Table 1 illustrates two important results. First,
APOE"4 is associated with lower testosterone l vels
in men, but only significantly so in controls. Second,
testosterone levels are higher in controls than in AD,
but only in men without APOE"4. These results are
open to various interpretations. One is that APOE"4,
among other factors, lowers testosterone in male con-
trols and low testosterone, whether or not due to
APOE"4 status, contributes to the onset of AD.
Another interpretation is that APOE"4 lowers testos-
terone in controls and that AD results in a lowering of
testosterone levels for other reasons. This study can-
not distinguish between these interpretations. Pro-
spective studies are needed to resolve these issues.
Low testosterone is potentially a modifiable risk
factor. At present, no long-term studies have investi-
gated the possibly protective effects of testosterone
against the development of AD. Short-term studies
with testosterone replacement therapy in non-
demented men have given mixed results (Wolf et al.,
1999). A possible explanation could be that, since
APOE"4-positive controls had lower levels in the pre-
sent study than those without the allele, perhaps only
APOE"4-positive men would profit from testosterone
replacement therapy. Future, long-term studies should
investigate the possibly protective effect of testoster-
one replacement therapy in APOE"4 carriers who are
at risk of AD.
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